Study Protocol for Pleiotropic Effects and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Versus Sulfonylurea in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

Yumie Takeshita, Takehiro Kanamori, Takeo Tanaka, Yuka Kaikoi, Yuki Kita, Noboru Takata, Noriho Iida, Kuniaki Arai, Tatsuya Yamashita, Kenichi Harada, Toshifumi Gabata, Hiroyuki Nakamura, Shuichi Kaneko, Toshinari Takamura, Yumie Takeshita, Takehiro Kanamori, Takeo Tanaka, Yuka Kaikoi, Yuki Kita, Noboru Takata, Noriho Iida, Kuniaki Arai, Tatsuya Yamashita, Kenichi Harada, Toshifumi Gabata, Hiroyuki Nakamura, Shuichi Kaneko, Toshinari Takamura

Abstract

Introduction: Clinicopathological analyses revealed that reduction in HbA1c and use of insulin independently contribute to reduction in liver fibrosis scores during the course of nonalcoholic fatty liver disease (NAFLD) development. We will test our hypothesis that lowering glucose and increasing insulin reduce liver fibrosis in NAFLD. Sodium-glucose cotransporter 2 (SGLT2) inhibitors lower insulin levels and sulfonylureas increase insulin levels, while both lower glucose levels.

Methods: This study is a 48-week, one-center (only Kanazawa University Hospital), open-label, randomized, parallel trial. Patients who satisfied the eligibility criteria were randomly assigned (1:1) to receive once-daily 20 mg tofogliflozin or 0.5 mg glimepiride. The sample size was calculated to be 14 in each group with a significance level of 0.05 and power of 0.90. The design required 40 evaluable patients in this study. The primary endpoint of this study will be the improvement in liver histology between liver biopsies at baseline and after 48 weeks of treatment. The secondary efficacy endpoints in the present study include organ-specific insulin sensitivity, insulin/glucagon secretion, ectopic fat accumulation, bioelectrical impedance analysis, sympathetic nerve activity, comprehensive gene expression analyses in the liver and blood cells, and gut microbiota profiling.

Planned outcomes: Recruitment into this study started in November 2015 and will end in September 2020, with 40 patients randomized into the two groups. The treatment follow-up of the participants is currently ongoing and is due to finish by the end of 2022. The findings of this trial will be disseminated through peer-reviewed publications and international presentations.

Trial registration: This trial is registered with the University Hospital Medical Information Network Clinical Trials Registry (UMIN000020544) and ClinicalTrials.gov (NCT02649465).

Keywords: Nonalcoholic fatty liver disease; Sodium–glucose cotransporter 2 inhibitor; Sulfonylurea; Treatment strategies; Type 2 diabetes.

Figures

Fig. 1
Fig. 1
Flow chart of the study schedule

References

    1. Hamaguchi E, Takamura T, Sakurai M, et al. Histological course of nonalcoholic fatty liver disease in Japanese patients: tight glycemic control, rather than weight reduction, ameliorates liver fibrosis. Diabetes Care. 2010 doi: 10.2337/dc09-0148.
    1. Davies MJ, D’Alessio DA, Fradkin J, et al. Correction to: management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetologia. 2019;62:873. doi: 10.1007/s00125-019-4845-x.
    1. Bolinder J, Ljunggren Ö, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97:1020–1031. doi: 10.1210/jc.2011-2260.
    1. Hayashizaki-Someya Y, Kurosaki E, Takasu T, et al. Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats. Eur J Pharmacol. 2015;754:19–24. doi: 10.1016/j.ejphar.2015.02.009.
    1. Honda Y, Imajo K, Kato T, et al. The selective SGLT2 inhibitor ipragliflozin has a therapeutic effect on nonalcoholic steatohepatitis in mice. PLoS One. 2016;11:1–13. doi: 10.1371/journal.pone.0146337.
    1. Obata A, Kubota N, Kubota T, et al. Tofogliflozin improves insulin resistance in skeletal muscle and accelerates lipolysis in adipose tissue in male mice. Endocrinology. 2016;157:1029–1042. doi: 10.1210/en.2015-1588.
    1. Kuchay MS, Krishan S, Mishra SK, et al. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial) Diabetes Care. 2018;41:1801–1808. doi: 10.2337/dc18-0165.
    1. Sumida Y, Murotani K, Saito M, et al. Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease: a prospective, single-arm trial (LEAD trial) Hepatol Res. 2019;49:64–71. doi: 10.1111/hepr.13236.
    1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53. .
    1. Sakurai M, Takamura T, Ota T, et al. Liver steatosis, but not fibrosis, is associated with insulin resistance in nonalcoholic fatty liver disease. J Gastroenterol. 2007;42:312–317. doi: 10.1007/s00535-006-1948-.
    1. Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467–2474. doi: 10.1111/j.1572-0241.1999.01377.x.
    1. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–1321. doi: 10.1002/hep.20701.
    1. Iida N, Mizukoshi E, Yamashita T, et al. Overuse of antianaerobic drug is associated with poor postchemotherapy prognosis of patients with hepatocellular carcinoma. Int J cancer. 2019 doi: 10.1002/ijc.32339.
    1. Takeshita Y, Takamura T, Honda M, et al. The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial. Diabetologia. 2014 doi: 10.1007/s00125-013-3149-9.
    1. Tsuchiyama N, Takamura T, Ando H, et al. Possible role of alpha-cell insulin resistance in exaggerated glucagon responses to arginine in type 2 diabetes. Diabetes Care. 2007;30:2583–2587. doi: 10.2337/dc07-0066.
    1. Pang JXQ, Zimmer S, Niu S, et al. Liver stiffness by transient elastography predicts liver-related complications and mortality in patients with chronic liver disease. PLoS One. 2014;9:e95776. doi: 10.1371/journal.pone.0095776.
    1. Cobelli C, Mari A, Ferrannini E. Non-steady state: error analysis of Steele’s model and developments for glucose kinetics. Am J Physiol. 1987;252:E679–E689. doi: 10.1152/ajpendo.1987.252.5.E679.
    1. Kato K, Takamura T, Takeshita Y, et al. Ectopic fat accumulation and distant organ-specific insulin resistance in Japanese people with nonalcoholic fatty liver disease. PLoS One. 2014;9:e92170. doi: 10.1371/journal.pone.0092170.
    1. Frayn KN. Calculation of substrate oxidation rates in vivo from gaseous exchange. J Appl Physiol. 1983;55:628–634. doi: 10.1152/jappl.1983.55.2.628.
    1. Yokoyama H, Mori K, Emoto M, et al. Non-oxidative glucose disposal is reduced in type 2 diabetes, but can be restored by aerobic exercise. Diabetes Obes Metab. 2008;10:400–407. doi: 10.1111/j.1463-1326.2007.00716.x.
    1. Ryysy L, Häkkinen AM, Goto T, et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes. 2000;49:749–758. doi: 10.2337/diabetes.49.5.749.
    1. Perini R, Veicsteinas A. Heart rate variability and autonomic activity at rest and during exercise in various physiological conditions. Eur J Appl Physiol. 2003;90:317–325. doi: 10.1007/s00421-003-0953-9.
    1. Bonetti PO, Pumper GM, Higano ST, et al. Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol. 2004;44:2137–2141. doi: 10.1016/j.jacc.2004.08.062.
    1. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675–1685. doi: 10.1056/nejmoa0907929.pioglitazone.
    1. Ratziu V, Charlotte F, Bernhardt C, et al. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the Fatty Liver Improvement by Rosiglitazone Therapy (FLIRT 2) extension trial. Hepatology. 2010;51:445–453. doi: 10.1002/hep.23270.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する